Longeveron (NASDAQ:LGVN) is a biotechnology firm focused on developing cellular therapies for aging-related and life-threatening conditions. The company's innovative research is dedicated to harnessing the potential of regenerative medicine to address the unmet needs of diseases such as aging frailty, metabolic disorders, and Alzheimer’s disease, among others. With a commitment to improving human health and longevity, Longeveron continues to advance its clinical studies and expand its pipeline of therapeutic candidates. The firm aims to lead the way in cellular therapy development, focusing on rigorous science and clinical trials to bring new treatments from the lab to the patients who need them most.